Compositions and methods for treating refractory or intractable epilepsy
Patent Information
- Application Number
- PCT/US2024/032877
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2023-06-06
- Filing Date
- 2024-06-06
- Publication Date
- 2024-12-12
Smart Images

Figure US2024032877_12122024_PF_FP_ABST
Abstract
Description
COMPOSITIONS AND METHODS FOR TREATING REFRACTORY OR INTRACTABLE EPILPSY Cross Reference to Related Applications
[0001] This application claims priority to U.S. Application No.63 / 506,591 filed on June 6, 2023, the disclosure of which is incorporated by reference. Field of Invention
[0002] The invention relates to compositions and methods for treating disorders that are responsive to a ketogenic diet. Background
[0003] The ketogenic diet (KD) is now a proven therapy for drug-resistant epilepsy (Vining et al., 1998; Neal et al., 2008), and while the mechanisms underlying its anticonvulsant effects remain incompletely understood (Hartman et al., 2007; Bough and Stafstrom, 2010; Rho and Stafstrom, 2011), there is mounting experimental evidence for its broad neuroprotective properties and, in turn, emerging data supporting its use in multiple neurological disease states(Baranano and Hartman, 2008). Even in patients with medically refractory epilepsy who have remained seizure-free on the KD for 2 years or more, it is not uncommon for clinicians to observe that both anticonvulsant medications and the diet can be successfully discontinued without recrudescence of seizures (Freeman et al., 2007). This intriguing clinical observation forms the basis of the hypothesis that the KD may possess anti-epileptogenic properties. An underlying theme of such diet- based therapies is that nutrients and metabolic substrates can exert profound effects on neuronal plasticity, modifying neural circuits and cellular properties to enhance and normalize function. At a fundamental level, any disease in which the pathogenesis is influenced by abnormalities in cellular energy utilization – and this implies almost every known condition – would theoretically be amenable to the KD. Diet and nutrition influencing brain function should not be altogether surprising, and there are already abundant clinical and laboratory data linking defects in energy metabolism to a wide variety of disease states (Waldbaum and Patel, 2010; Roth et al., 2011; Schiff et al., 2011).
[0004] There is no longer any doubt that the KD is effective in ameliorating seizures in patients, especially children, with medically refractory epilepsy (Vining, 1999; Neal et al., 2008; Freeman et al., 2009). After its introduction in 1920, the KD was used as afirst or second-line treatment for severe childhood epilepsy. Recent years have witnessed a remarkable surge in research on the KD, including basic science efforts as well as clinical protocols and trials (Kim do and Rho, 2008; Neal et al., 2008; Kessler et al., 2011). The KD has now become an integral part of the armamentarium of most major epilepsy centers throughout the world (Kossoff and McGrogan, 2005).
[0005] Aging involves the gradual decrease in function, and at times outright degeneration, of neurons and neural circuits. It is possible that by altering energy metabolism with the KD, rates of degeneration ofcertain neural structures and functions might be slowed (Balietti et al., 2010a). However, KDs may induce differential morphological effects in structures such as the hippocampus, perhaps as a consequence of region-specific neuronal vulnerability during the late aging process (Balietti et al., 2008). Specifically, it has been shown that the medium-chain triglyceride (MCT) form of the KD may induce detrimental synaptic changes in CA1 stratum moleculare, but beneficial effects in the outer molecular layer of the dentate gyrus (Balietti et al., 2008). In MCT-fed aged rats compared to aged rats receiving a normal diet, mitochondrial density and function in cerebellar Purkinje cells were significantly increased, suggesting that the KD can rescue age-related mitochondrial dysfunction (Balietti et al., 2010b). These observations imply certain risks, but also potential benefits of the KD for the aging brain. However, the fact that the KD reduces oxidative stress, and its downstream consequences provides a reasonable rationale for considering this type of treatment to retard the adverse consequences during aging (Freemantle et al., 2009). As an example, T-maze and object recognition performance were improved in aged rats by KD administration, suggesting a potential functional benefit in cognition (Xu et al., 2010).
[0006] There is growing realization that neuronal excitability is enhanced in patients with Alzheimer disease (AD; Noebels, 2011; Roberson et al., 2011). While the essential pathological process of AD involves neuronal degeneration with accumulation of abnormal cellular products such asfibrillary plaques and tangles, recent evidence points to alterations in the function of extant neural circuits and mitochondrial homeostasis (Kapogiannis and Mattson, 2011). This view is bolstered by the higher incidence of seizures in patients with AD as compared to the unaffected population (Palop and Mucke, 2009). Therefore, there is a rationale that the KD might have a beneficial role in patients with AD (Balietti et al., 2010a), in addition to the potential benefits to the aging process as noted above. One should note, importantly, that if ketone bodies are indeed the primary mediators that counter aging and neurodegeneration in AD, implementation of the KD should be tempered by known age-related differences in the production and extraction of ketones (i.e., this is more efficient in young animals), as well as age-specific regional differences in ketone utilization within the brain (Nehlig, 1999). A randomized double-blind, placebo-controlled trial of a MCT KD resulted in significantly improved cognitive functioning in APOε4-negative patients with AD but not in patients with a APOε4 mutation (Henderson et al., 2009). In this study, the primary cognitive endpoints measured were the mean change from baseline in the AD Assessment Scale-Cognitive subscale, and global scores in the AD Cooperative Study – Clinical Global Impression of Change (Henderson et al., 2009). This significant clinical improvement was considered to be secondary to improved mitochondrial function, since ketone bodies (specifically, beta-hydroxybutyrate or BHB) have been shown to protect against the toxic effects of β- amyloid on neurons in culture (Kashiwaya et al., 2000). Alternatively, the KD may actually decrease amounts of β-amyloid deposition (Van der Auwera et al., 2005). Recent studies have shown a closer linkage of AD to epilepsy. For example, animal models of AD exhibit neuronal hyperexcitability and enhanced propensity toseizures (Palop et al., 2007; Roberson et al., 2011); these models may ultimately allow for detailed analyses of both cognitive and anticonvulsant effects of the KD or other dietary manipulations such as calorie restriction. Transgenic AD mice fed 2DG demonstrated better mitochondrial function, less oxidative stress, and reduced expression of amyloid precursor protein and β-amyloid compared to control animals (Yao et al., 2011). Thus, there is growing evidence that the KD may be an effective treatment for AD through a variety of metabolism-induced mechanisms that reduce oxidative stress and neuroinflammation and enhance bioenergetic profiles – largely through enhanced mitochondrial functioning.
[0007] The primary pathophysiology in Parkinson disease (PD) is excitotoxic degeneration of dopaminergic neurons in the substantia nigra, leading to abnormalities of movement, and to an increasing extent, in cognition and other cortical functions. Based on the recognition that ketone bodies may bypass defects in mitochondrial complex I activity that have been implicated in PD, a small clinical study demonstrated that 5 of 7 affected patients showed improved scores on a standard PD rating scale (Vanitallie et al., 2005). In animal models of PD produced by 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP), BHB administration ameliorated the mitochondrial respiratory chain damage that ordinarily results from that toxin (Kashiwaya et al., 2000). Additional evidence supporting the potential benefits of ketone bodies in PD is provided by in vitro experiments demonstrating the protective effects of these substrates against mitochondrial respiratory chain dysfunction induced exogenously by complex I and II inhibitors rotenone and 3-nitropropionic acid, respectively (Kim do et al., 2010), and even anti-inflammatory actions of the KD on MPTP-induced neurotoxicity (Yang and Cheng, 2010).
[0008] Amyotrophic lateral sclerosis (ALS) is a rapidly progressive disease due to degeneration of motor neurons of the cortex and anterior horn of the spinal cord. Consequently, voluntary motor activity gradually deteriorates, leaving the affected individual profoundly weak despite largely retained cognitive functioning. The essential pathophysiological mechanisms that underlie this relentless disorder are yet to be fully elucidated, but similar to other neurodegenerative disorders, the involvement of energy-producing systems likely play a role and mitochondrial dysfunction probably contributes to disease pathogenesis. In this regard, the KD may be a promising adjunctive treatment for this devastating disease (Siva, 2006), as evidenced in a mouse model of ALS, produced by knocking out the gene encoding the copper / zinc superoxide dismutase SOD1-G93A, causing progressive muscle weakness and death by respiratory failure. Administration of a KD to these mutant mice led to both histological (higher motor neuron counts) and functional improvements (preserved motor function on the rotorod test) compared to non-KD fed animals (Zhao et al., 2006). Mitochondria from these mutant mice demonstrated increased ATP synthesis, countering the inhibition of complex I of the electron transport chain. It is important to note that approximately 20% of the familial cases of ALS have SOD1 mutations, and hence the possibility arises that the KD may be of benefit to patients with ALS.
[0009] Cells that exhibit the most active metabolic rates (i.e., cancer cells) are most sensitive to the lack of metabolic energy to fuel their activity, a well-recognized biochemical phenomenon known as the Warburg effect. Theoretically, depriving rapidly dividing, highly metabolic cancer cells of their usual fuel supply, e.g., glucose (by use of the KD or 2DG), could be clinically therapeutic (Aft et al., 2002; Pelicano et al., 2006; Otto et al., 2008). Despite this well documented cellular observation, the KD has only recently been considered as a clinical treatment in the oncologyfield. Pioneering work by Seyfried et al. (2011) over the past decade has shown that animals with experimentally produced brain tumors placed on a KD exhibit markedly decreased tumor growth rates, and these remarkable effects appear to be a consequence of calorie restriction (i.e., reduced blood glucose levels) rather than KD-induced ketosis (i.e., fatty acid oxidation) as the principal mechanism. Other investigators have found similar effects of the KD in animal models. One group found that the KD reduces ROS production in malignant glioma cells, and gene microarray expression profiling demonstrated that the KD induces an overall reversion to patterns seen in non-tumor specimens and a reduction in the expression of genes encoding signal trans- duction pathways and growth factors known to be involved in glioma growth (Stafford et al., 2010). It is also interesting to note that PPARα-activated by nutrients such as fatty acids – is now a target for developing anti-cancer drugs that target mitochondrial metabolism (Grabacka et al., 2010). While clinical validation of this phenomenon is not yet forthcoming, there are several case reports suggesting that the KD may be efficacious in humans with brain tumors. Nebeling et al. (1995) reported beneficial effects of an MCT-based diet in two pediatric patients with advanced stage malignant astrocytomas. More recently, Zuccoli et al. (2010) described a case study of an elderly woman with glioblastoma multiforme who was treated with standard radiotherapy plus concomitant temozolomide therapy together with a calorie-restricted KD, and a complete absence of brain tumor tissue was noted on FDT–PET and MRI imaging after 2 months of treatment – results the authors attributed in part to the adjunctive dietary treatment. Further, in a pilot trial of the KD in 16 patients with advanced metastatic tumors, six individuals reported improved emotional functioning and less insomnia, indicating that in some instances, the KD may lead to improved quality of life (Schmidt et al., 2011).
[0010] Several animal studies of hypoxia-ischemia support the potential beneficial effect of the diet. Most of these models entail pre-treatment with the KD (or with BHB), resulting in decreased structural and functional damage from the stroke. For example, Tai et al. (2008) utilized a cardiac arrest model in rats and found significantly reduced Fluoro-Jade staining in animals that underwent 25 days of pretreatment with the KD. These investigators later determined that these effects were not due to involvement of plasmalemmal ATP-sensitive potassium channels (Tai et al., 2009), which have been implicated in ketone body action (Ma et al., 2007). Other researchers have hypothesized that the neuroprotective properties of ketone bodies might be related to up-regulation of hypoxia inducible factor (HIF1-α) which is important in angiogenesis and anti- apoptotic activity (Puchowicz et al., 2008). In that study, pre-treatment with BHB (via intraventricularinfusion, followed by middle cerebral artery occlusion) led to significant increases in brain succinate content, as well as elevations in HIF1-α and Bcl-2, an anti-apoptotic protein.
[0011] As mentioned above, given the growing evidence that the KD enhances mitochondrial functioning and biogenesis (Bough et al., 2006; Maalouf et al., 2009; Kim do et al., 2010), it is logical to ask whether patients with known mitochondrial cytopathies might derive a benefit from the KD and / or ketone bodies such as BHB. At the same time, it must be considered that inherent mitochondrial dysfunction might predispose individuals to adverse toxicities from high fatty acid loads that could overwhelm β-oxidation within the mitochondrial matrix. Experimental data described above attest to significant improvements in mitochondrial function, and many lines of evidence point to the rationale of therapeutically targeting mitochondrial bioenergetics for other disease states (Wallace et al., 2010). Kang et al. (2007) reported that the KD was both safe and effective in 14 pediatric patients with established mitochondrial defects in complexes I, II, and IV, all of whom had medically intractable epilepsy. These authors observed that half of these patients became seizure-free on the KD, and only four patients failed to respond. Hence, these preliminary data suggest that the KD is not necessarily contraindicated in patients with mitochondrial respiratory chain abnormalities.
[0012] Unfortunately, the incidence of brain injury is increasing in both civilian and military contexts. Brain injury, either due to a penetrating injury or to blunt / blast trauma, can lead to severe cognitive and motor consequences. Further, the occurrence of epilepsy months to years following brain trauma adds to the morbidity of affected individuals and speaks to the emergence of hyperexcitable neuronal circuits over time. Hence, considering the clinical problem of post-traumatic epileptogenesis and the fact that the KD can reduce seizure activity, the notion has emerged that dietary therapy might ameliorate brain injury and possibly, long-term consequences such as epilepsy. Several recent animal studies support this idea, and investigators have principally focused on ketone bodies (Prins, 2008a). Using a controlled cortical impact (CCI) injury model, Prins et al. (2005) showed that pre-treatment with a KD significantly reduced cortical contusion volume in an age-related manner that correlated with maturation-dependent differences in cerebral metabolism and ketone utilization. Later, they showed that cognitive and motor functioning was also improved with KD treatment (Appelberg et al., 2009). Further, using a weight drop model, Hu et al. (2009) showed that the KD pre-treatment reduced Bcl-2 (also known as Bax) mRNA and protein levels 72 h after trauma, indicating that apoptotic neurodegeneration could be prevented with this diet. Consistent with these observations, it was found that fasting – which shares the key feature of ketosis with the KD – led to significant tissue sparing in brain following CCI injury, and that again ketosis (with improved mitochondrial functioning) rather than the relative hypoglycemia seen with fasting was the important determinant of neuroprotection (Davis et al., 2008).
[0013] Autism is a neurodevelopmental disorder that affects language development and social function. The heterogeneous etiologies leading to autism spectrum disorders, plus the uncertainty about what causes autism in the majority of “idiopathic” cases, has hampered the development of a universally beneficial treatment, aside from symptomatic treatment of autism-related behaviors such as aggression or anxiety. Now, limited clinical evidence raises the intriguing possibility that the KD might be helpful to alleviate some of the abnormal behaviors seen in children with autism spectrum disorders. Using a KD variant consisting of MCT, 10 of 18 autistic children demonstrated moderate or significant behavioral improvement (by a blinded rater) after a 6-month trial of providing the diet for 4 weeks of KD diet treatment alternating with 2 weeks of normal diet, in 6-week cycles (Evangeliou et al., 2003). This study was carried out on the island of Crete, where the frequency of autism is high but the possibility of genetic inbreeding is also significant.
[0014] Migraine is a paroxysmal neurological disorder having considerable clinical phenotypic overlap with epilepsy (Rogawski, 2008). Although the intrinsic mechanisms underlying seizures and migraine attacks differ in many fundamental respects, there are theoretical reasons to consider the KD for chronic migraine. Both disorders involve paroxysmal excitability changes in the brain, and there is considerable overlap in the array of pharmacological agents used to treat these conditions. Although it might seem unlikely that an individual with migraine would undertake such a complicated dietary regimen as the KD, in light of suboptimal alternatives, this choice is worthy of consideration, particularly in the medically refractory population (Maggioni et al., 2011).
[0015] Interestingly, thefirst report of using the KD for migraine came in 1928, only a few years after the diet’sfirst use for epilepsy (Schnabel, 1928). Nine of 28 patients reported “some improvement”. Compliance might be better with the less restrictive modified Atkins diet, which has also shown promise for migraine treatment (Kossoff et al., 2010). Laboratory investigations have found that both short-term and long-term treatment with either MCT or long-chain triglyceride forms of the KD resulted in a significant reduction in the velocity of cortical spreading depression (CSD) velocity in immature rats (de Almeida Rabello Oliveira et al., 2008). Another intriguing aspect of this study was the observation that triheptanoin – an anaplerotic substrate that enhances tricarboxylic acid cycle function – had a notable effect in retarding CSD, consistent with a later report that triheptanoin supplementation raised pentylenetetrazol tonic seizure threshold and delayed the development of corneal kindled seizures (Willis et al., 2010).
[0001] SGLT1 inhibitors partially or completely block glucose absorption into the body. This promotes ketogenesis and thus is comparable to a KD. Thus, SGLT2 inhibitors are effective for treating disorders that are responsive to a KD. Summary of the Invention
[0016] Applicant recognized that subjects with disorders that are responsive to ketogenic diets are also responsive to inhibitors of sodium-dependent glucose transporter (SGLT). Thus, according to one aspect ofthe invention, methods of treating a disorder in a subject in need thereof administer one or more SGLT1 inhibitors or a pharmaceutically acceptable salts thereof, to the subject.
[0017] A disorder treated by a method of the invention is, in certain embodiments, a neurological disorder, including, but not limited to neurological seizures, epilepsy, Dravet’s Syndrome, stroke, brain trauma, depression, mitochondrial defects in complexes I, II, and IV, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer autism, or migraine.
[0018] Another disorder treated by a method of the invention is cancer or type 2 diabetes mellitus that is primarily driven by elevated postprandial glucose levels. Brief Description of the Figures
[0019] FIG.1 shows effects of a single dose of mizagliflozin and voglibose on plasma glucose levels in normal rats following mixed carbohydrate load.
[0020] FIG.2 shows effects of mizagliflozin and voglibose on ΔAUC0-1hrin normal rats following oral mixed carbohydrate load.
[0021] FIG.3 shows effects of mizagliflozin and voglibose on mean ΔAUC0-1 hr(% of control) in normal rats following oral mixed carbohydrate load.
[0022] FIG.4 shows effects of mizagliflozin and voglibose on oral glucose excursion in STZ-induced diabetic rats following oral mixed carbohydrate load.
[0023] FIG.5 shows effects of mizagliflozin and voglibose on the ΔAUC0-1 hrin STZ-induced diabetic rats following oral mixed carbohydrate load.
[0024] FIG.6 shows effects of mizagliflozin and voglibose on oral glucose excursion in STZ-induced diabetic rats following OGTT.
[0025] FIG.7 shows effects of mizagliflozin and voglibose on the ΔAUC0-1 hrin STZ-induced diabetic rats following OGTT.
[0026] FIG.8 shows dose-response relationships for mean ΔAUC0-1hr(% of control) in response to mizagliflozin and voglibose after OGTT in STZ-induced diabetic rats.
[0027] FIG.9 shows effects of mizagliflozin on oral glucose excursions in DIO marmosets.
[0028] FIG.10 shows the Dixon plots used to calculate the inhibition constant of mizagliflozin (KGA-3235) for human SGLT1. Subjects were fasted overnight and dosed with 2.5 mg, 5.0 mg, or 10.0 mg mizagliflozin in capsules or 2.5 mg mizagliflozin liquid formulation. After 20 minutes, subjects ingested a mixed meal and afterwards, glucose and insulin levels were measured over 6 hours. These data were compared to a baseline measurement taken previously in the absence of mizagliflozin. Detailed Description
[0029] The invention generally relates to methods of treatment of a variety of disorders that have been shown to be treatable with a ketogenic diet (KD). By administering SGLT1 inhibitors, our data shows a partialor complete blocking of glucose absorption into the body. This promotes ketogenesis and thus is comparable to a KD. In particular, the invention relates to a method of treating a subject with neuronal disorders that lead to seizure, comprising the step of orally administering mizagliflozin, or a pharmaceutically acceptable salt thereof to said subject.
[0030] Mizagliflozin, 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl- ]-3- methylphenoxy}propylamino)-2,2-dimethylpropionamide, is a SGLT1 inhibitor. Mizagliflozin can be converted to a pharmaceutically acceptable salt according to methods known in the art. Examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, acid addition salts with organic acids such as formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, propionic acid, citric acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid and the like, salts with inorganic bases such as a sodium salt, a potassium salt and the like, and salts with organic bases such as N-methyl-D-glucamine, N,N'- dibenzyletylenediamine, 2-aminoethanol, tris (hydroxymethyl)aminomethane, arginine, lysine and the like. Mizagliflozin, 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl-]-3- methylphenoxy}propylamino)-2,2-dimethylpropionamide, is a SGLT1 inhibitor created by Kissei Pharmaceutical Co., Ltd. No SGLT1 inhibitors have been approved to date. Mizagliflozin suppresses the uptake of glucose from the digestive tract by selectively inhibiting SGLT1. In addition, it acts primarily in the upper part of the small intestine and has a weak inhibitory effect on glucose absorption in the lower part of the small intestine since it is broken down and deactivated as it moves through the digestive tract. Gastrointestinal symptoms are not readily likely if the amount of glucose that remains without being absorbed is small.
[0031] Blocking human SGLT1 activity inhibits absorption of carbohydrates such as glucose at the small intestine, and subsequently can prevent increase of blood sugar level. Since increase of SGLT1 in the small intestine is thought to contribute to increased carbohydrate absorption, fast development of agents, which have a potent inhibitory activity in human SGLT1, has been desired for the prevention or treatment of diabetes. U.S. Patent No.8,324,176. Crystalline compounds of mizagliflozin have been described for use of prevention or treatment of a disease associated with hyperglycemia such as diabetes, impaired glucose tolerance, impaired fasting glycemia, diabetic complications or obesity, and a disease associated with the increase in blood galactose level such as galactosemia. U.S. Patent Nos.8,399,418 describes the monosebacate salt of mizagliflozin, and U.S. Patent No.8,354,382 describes the hemifumarate dehydrate salt of mizagliflozin. U.S. Patent No.11,596,644 describes the use of Mizagliflozin to treat post-bariatric hypoglycemia. By restricting the amount of dietary glucose absorbed into the body, SGLT1 inhibitors such as mizagliflozin can induce a ketogenic diet.
[0032] In a method of the invention, the pharmaceutical salt is selected from mizagliflozin monosebacate and mizagliflozin hemifumarate dehydrate. Mizagliflozin hemifumarate dihydrate, from U.S. Patent No. 8,354,382, is shown below:Mizagliflozin monosebacate, from U.S. Patent No.8,399,418, is shown below:
[0033] Neuronal disorders leading to seizure include, but are not limited to epilepsy, intractable epilepsy, medically refractory epilepsy, Dravet’s Syndrome, Parkinson’s Disease, Alzheimer’s Disease, stroke, brain trauma, head injury, Rasmussen's encephalitis. In a method of the invention, the seizure is associated with a disease that is treatable with a KD.
[0034] In an effective therapy, mizagliflozin inhibits glucose uptake in the intestine, reducing the postprandial rise in plasma glucose concentration and thereby reduce the amount of glucose available to the rest of the body. This effect would act as a ketogenic diet. In a series of preclinical studies performed in normal rats, diabetic rats and in diet-induced obese marmosets, when administered prior to a meal challenge (oral glucose or mixed meal tolerance test), mizagliflozin significantly reduced the peak postprandial glucose concentration and the total ΔAUC0-1h. The preclinical data disclosed below demonstrate that mizagliflozin can prevent the postprandial spike in plasma glucose concentration. In addition, clinical studies demonstrating the effect of mizagliflozin on postprandial glucose and insulin have also been conducted in healthy human volunteers and in subjects with type 2 diabetes (examples provided below). In these studies, subjects were administered mizagliflozin prior to an oral glucose tolerance or mixed meal tolerance test. Results from these clinical studies demonstrated that treatment with mizagliflozin, prior to ameal challenge, reduced the peak postprandial plasma glucose concentration. These data are highly supportive of the ability of mizagliflozin to blunt the hyperglycemic hyperinsulinemic response and act as a KD.
[0035] In a method of the invention, the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered at a dosage of from about 1 mg / day to about 160 mg / day. For example the dosage is 1 mg / day, 2 mg / day, 3 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 30 mg / day, 40 mg / day, 50 mg / day, 60 mg / day, 70 mg / day, 80 mg / day, 90 mg / day, 100 mg / day, 110 mg / day, 120 mg / day, 130 mg / day, 140 mg / day, 150 mg / day, or 160 mg / day. Preferably , the dosage is from about 1 mg / day to about 20 mg / day. For example, the dosage is 1 mg / day, 2 mg / day, 3 mg / day, 4 mg / day, 5 mg / day, 6 mg / day, 7 mg / day, 8 mg / day, 9 mg / day, 10 mg / day, 11 mg / day, 12 mg / day, 13 mg / day, 14 mg / day, 15 mg / day, 16 mg / day, 17 mg / day, 18 mg / day, 19 mg / day, or 20 mg / day.
[0036] In a method of the invention, the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered at a dosage of from about 1 mg to about 20 mg, three times a day. For example, the dosage is 1 mg, three times a day; 2 mg, three times a day; 3 mg, three times a day; 4 mg, three times a day; 5 mg, three times a day; 6 mg, three times a day; 7 mg, three times a day; 8 mg, three times a day; 9 mg, three times a day; 10 mg, three times a day; 11 mg, three times a day; 12 mg, three times a day; 13 mg, three times a day; 14 mg, three times a day; 15 mg, three times a day; 16 mg, three times a day; 17 mg, three times a day; 18 mg, three times a day; 19 mg, three times a day; or 20 mg, three times a day;. In a preferred method of the invention, the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered after a meal. For example, the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered once after breakfast, once after lunch, and once after dinner, daily.
[0037] Unless otherwise indicated, a “therapeutically effective amount” of a compound is an amount sufficient to provide a therapeutic benefit in the treatment or management of a disease or condition, or to delay or minimize one or more symptoms associated with the disease or condition. A “therapeutically effective amount” of a compound means an amount of therapeutic agent, alone or in combination with other therapies, which provides a therapeutic benefit in the treatment or management of the disease or condition. The term “therapeutically effective amount” can encompass an amount that improves overall therapy, reduces or avoids symptoms or causes of a disease or condition, or enhances the therapeutic efficacy of another therapeutic agent.
[0038] The terms “treat,” “treating,” and “treatment” contemplate an action that occurs while a patient is suffering from the specified disease or disorder, which reduces the severity of the disease or disorder, or retards or slows the progression of the disease or disorder.
[0039] It should also be noted that if the stereochemistry of a structure or a portion of a structure is not indicated with, for example, bold or dashed lines, the structure or the portion of the structure is to beinterpreted as encompassing all stereoisomers of it. Moreover, any atom shown in a drawing with unsatisfied valences is assumed to be attached to enough hydrogen atoms to satisfy the valences. In addition, chemical bonds depicted with one solid line parallel to one dashed line encompass both single and double (e.g., aromatic) bonds, if valences permit.
[0040] Disorders that are treated or ameliorated by a method of the invention include, but are not limited to neurological seizures, type 2 diabetes mellitus that is primarily driven by elevated postprandial glucose levels, epilepsy, Dravet’s Syndrome, stroke, brain trauma, depression, mitochondrial defects in complexes I, II, and IV, Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer disease, cancer, autism, migraine.
[0041] For the methods of the invention, SGLT1 inhibitors of Formula I and Formula II can be prepared by methods known in the art. See e.g., U.S. Patent No.7,635,684, and U.S. Patent No.9,200,025.
[0042] In a preferred method of the invention, SGLT1 inhibitors of Formula I and Formula II are selected from the group consisting of:
[0043] In some preferred methods of the invention, the SGLT1 inhibitor is selected from LX2671 and mizagliflozin. In an even more preferred method of the invention, the SGLT1 inhibitor is mizagliflozin. Mizagliflozin, 3-(3-{4-[3-(β-D-glucopyranosyloxy)-5-isopropyl-1H-pyrazol-4-ylmethyl- ]-3- methylphenoxy}propylamino)-2,2-dimethylpropionamide, can be converted to a pharmaceutically acceptable salt according to methods known in the art. Examples of such salts include acid addition salts with mineral acids such as hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, nitric acid, phosphoric acid and the like, acid addition salts with organic acids such as formic acid, acetic acid, methanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, propionic acid, citric acid, succinic acid, tartaric acid, fumaric acid, butyric acid, oxalic acid, malonic acid, maleic acid, lactic acid, malic acid, carbonic acid, glutamic acid, aspartic acid and the like, salts with inorganic bases such as a sodium salt, a potassiumsalt and the like, and salts with organic bases such as N-methyl-D-glucamine, N,N'- dibenzyletylenediamine, 2-aminoethanol, tris (hydroxymethyl)aminomethane, arginine, lysine and the like.
[0044] In some methods of the invention where mizagliflozin is administered, the pharmaceutical salt is selected from mizagliflozin monosebacate and mizagliflozin hemifumarate dehydrate. Mizagliflozin hemifumarate dihydrate, from U.S. Patent No.8,354,382, is shown below:
[0045] Mizagliflozin monosebacate, from U.S. Patent No.8,399,418, is shown below:
[0046] In a method of the invention, the SGLT inhibitor compound of Formula I or Formula II is administered at a dosage of from about 0.1 mg / day to about 160 mg / day. For example the dosage is 0.1 mg / day, 0.2 mg / day, 0.5 mg / day, 1 mg / day, 2 mg / day, 3 mg / day, 5 mg / day, 10 mg / day, 20 mg / day, 30 mg / day, 40 mg / day, 50 mg / day, 60 mg / day, 70 mg / day, 80 mg / day, 90 mg / day, 100 mg / day, 110 mg / day, 120 mg / day, 130 mg / day, 140 mg / day, 150 mg / day, or 160 mg / day. Preferably , the dosage is from about 1 mg / day to about 60 mg / day. For example, the dosage is 1 mg / day, 2 mg / day, 3 mg / day, 4 mg / day, 5 mg / day, 6 mg / day, 7 mg / day, 8 mg / day, 9 mg / day, 10 mg / day, 11 mg / day, 12 mg / day, 13 mg / day, 14 mg / day, 15 mg / day, 16 mg / day, 17 mg / day, 18 mg / day, 19 mg / day, 20 mg / day, 21 mg / day, 24 mg / day, 27 mg / day, 30 mg / day, 33 mg / day, 36 mg / day, 39 mg / day, 42 mg / day, 45 mg / day, 48 mg / day, 51 mg / day, 54 mg / day, 57 mg / day, or 60 mg / day. In some methods of the invention the SGLT inhibitor compound ofFormula I or Formula II is administered as a pharmaceutically acceptable salt thereof. In such methods, the daily dose refers to the mg / day of the compound. A therapeutically effective amount for administration is determined by a treating physician.
[0047] The daily dose can be divided into one or more, for example, two or three- or four-unit doses administered per day A unit dose is the amount of compound administered at one time. In a preferred method of the invention, SGLT inhibitor compound of Formula I or Formula II is administered at a unit dose of from about 0.1 mg to about 20 mg, three times a day. For example, the dosage is 0.1 mg, three times a day; 0.2 mg, three times a day; 0.5 mg, three times a day; 1 mg, three times a day; 2 mg, three times a day; 3 mg, three times a day; 4 mg, three times a day; 5 mg, three times a day; 6 mg, three times a day; 7 mg, three times a day; 8 mg, three times a day; 9 mg, three times a day; 10 mg, three times a day; 11 mg, three times a day; 12 mg, three times a day; 13 mg, three times a day; 14 mg, three times a day; 15 mg, three times a day; 16 mg, three times a day; 17 mg, three times a day; 18 mg, three times a day; 19 mg, three times a day; or 20 mg, three times a day. In some methods of the invention the SGLT inhibitor compound of Formula I or Formula II is administered as a pharmaceutically acceptable salt thereof. In such methods, the unit dose refers to the mg of the compound.
[0048] In a preferred method of the invention, the SGLT inhibitor compound of Formula I or Formula II, or pharmaceutically acceptable salt thereof, is administered before a meal. For example, the SGLT inhibitor compound of Formula I or Formula II, or pharmaceutically acceptable salt thereof, is administered once before breakfast, once before lunch, and once before dinner, daily.
[0049] In methods according to the invention pharmaceutical compositions of SGLT1 inhibitor compounds of Formula I or Formula II, or pharmaceutically acceptable salt thereof, are employed using various dosage forms depending on their uses. Examples of orally administered dosage forms include powders, granules, fine granules, dry syrups, tablets, tablet triturates, chewable lozenges, rapidly dissolving tablets, multiple compressed tablets, uncoated tablets, enteric coated tablets, capsules and the like. Enteric-coated tablets are compressed tablets coated with substances that resist the action of stomach acid but dissolve or disintegrate in the intestine, thus protecting the active ingredients from the acidic environment of the stomach. Enteric coatings include, but are not limited to, fatty acids, fats, phenyl salicylate, waxes, shellac, ammoniated shellac, and cellulose acetate phthalates. Multiple compressed tablets are compressed tablets made by more than one compression cycle, including layered, press-coated, and dry-coated tablets. Tablets may also be coated using microencapsulation to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period. The pharmaceutical compositions of SGLT1 inhibitor compounds of Formula I or Formula II also include sustained release formulation including gastrointestinal mucoadhesive formulation (e.g., International publications Nos. WO99 / 10010, WO99 / 26606, and Japanese patent publication No.2001-2567).
[0050] The pharmaceutical compositions can be prepared by admixing with or by diluting and dissolving with an appropriate pharmaceutical additive such as excipients, disintegrators, binders, fillers, lubricants, diluents, buffers, isotonicities, antiseptics, moistening agents, emulsifiers, dispersing agents, stabilizing agents, dissolving aids and the like, and formulating the mixture in accordance with conventional methods. In case of the uses of the compound of SGLT1 inhibitor compounds of Formula I or Formula II in combination with the drug(s) other than SGLT1 inhibitors, they can be prepared by formulating each active ingredient together or individually.
[0051] Some compositions of the invention are formulated as oral dosage forms. For example, an oral dosage form of the invention may be a tablet that contains a dosage amount of mizagliflozin of 2.5 mg, 5 mg and 10 mg. A tablet of the invention, in one embodiment is a white to slightly yellowish white film-coated tablets with an oval shape of 8 mm×4.5 mm. Qualitative compositions of tablet excipients, in certain embodiments, may contain one or more of the excipients shown in Table 1. Tablets of the invention are typically stored in a tight sealed container closure system. Table 1
[0052] In some embodiments of the invention, the oral dosage form of mizagliflozin is a capsule. Table 2 shows exemplary capsule compositions. Table 2
[0053] In some methods of the invention, the SGLT1 inhibitor compound of Formula I or Formula II, or pharmaceutically acceptable salt thereof, is administered in combination with at least one glucagon-like peptide (GLP)-1 receptor antagonist. Preferably, the GLP-1 receptor antagonist is the peptide fragment of Exenatide, exendin 9-39. In the methods of the invention where the SGLT1 inhibitor compound of Formula I or Formula II, or pharmaceutically acceptable salt thereof, is administered in combination with such drugs, the dosage of the SGLT1 inhibitor compound of Formula I or Formula II can be decreased, depending on the dosage of the GLP-1 receptor antagonist. The disclosure of U.S. Patent No.11,596,644 describes studies that demonstrate mizagliflozin’ s selectivity for SGLT1 over SGLT2 as assessed by cellular uptake of radiolabeled methyl-α -D-glucopyranoside (α-MG) in vitro. Examples Example 1 - Study on normal rats
[0054] The efficacy of mizagliflozin (decreasing plasma glucose levels) in normal Sprague Dawley rats was determined in a mixed carbohydrate tolerance test. Normal rats were fasted for 16 hours and then given an oral loading dose of 2.0 g / kg of mixed carbohydrate (soluble starch:sucrose:lactose monohydrate = 6:3:1). Mizagliflozin, or water as the vehicle control, was then administered as a single oral dose to groups of male rats (n=8 / group) at doses of 0.03, 0.1, 0.3, and 1 mg / kg. Voglibose, a glucosidase inhibitor similar to acarbose, was used as a positive control and was administered as a single oral dose to male rats (n=8 / group) at dose levels of 0.1, 0.3 and 1 mg / kg. Blood samples were collected just prior to loading with mixed carbohydrate and at 0.5, 1, 2, 3, 4, and 6 hours after loading. Plasma glucose concentrations were determined and ΔAUC0-1h (the change in AUC) for plasma glucose was calculated.
[0055] Mizagliflozin reduced plasma glucose concentrations (FIG.1) and significantly lowered the ΔAUC0- 1h after loading of mixed carbohydrate when compared to the vehicle control (FIG.2). A significant decrease in ΔAUC0-1h was also seen after administration of voglibose. The 50% effective dose (ED50) calculated from the mean ΔAUC0-1h (% of control) for all dose levels of mizagliflozin was 0.130 mg / kg of mizagliflozin. The ED50 for voglibose was 0.320 mg / kg (FIG.3). Example 2 - Study in diabetic rats
[0056] Mizagliflozin was tested in a rat model for diabetes and efficacy, as measured by a relative decrease in plasma glucose was determined using a mixed carbohydrate tolerance test. Diabetic model rats were prepared by intravenous administration of streptozotocin (STZ) to induce diabetes. Seven days afterSTZ administration, rats were fasted for 16 hours and then given an oral loading dose of 2.0 g / kg of mixed carbohydrate (soluble starch:sucrose:lactose monohydrate = 6:3:1). Mizagliflozin, or water as the vehicle control, was then administered as a single oral dose to groups of male rats (n=8 / group) at doses of 0.01, 0.03, 0.1, and 0.3 mg / kg. Another control group was given vehicle and consisted of normal male Sprague Dawley rats that were not administered STZ. Voglibose was also administered as a single oral dose to male rats (n=8 / group) at dose levels of 0.03, 0.1 and 0.3 mg / kg. Blood samples were collected just prior to loading with mixed carbohydrate and at 0.5, 1, 2, 3, 4, and 6 hours after loading. Plasma glucose concentrations were determined and ΔAUC0-1h for plasma glucose was calculated.
[0057] Mizagliflozin reduced plasma glucose concentrations (FIG.4) and significantly lowered the ΔAUC0-1 hrin STZ-induced diabetic rats after loading of mixed carbohydrate when compared to the vehicle control (Figure 5). A significant decrease in ΔAUC0-1h was also seen after administration of voglibose. The ED50 calculated from the mean ΔAUC0-1h (% of control) for all dose levels of mizagliflozin was 0.096 mg / kg of mizagliflozin. Example 3 - Study in diabetic rats using oral glucose tolerance test
[0058] Efficacy of mizagliflozin was tested in a rat model for diabetes using an oral glucose tolerance test (OGTT). Diabetic model rats were prepared by intravenous administration of STZ to induce diabetes. Seven days after STZ administration, rats were fasted for 16 hours and then given an oral loading dose of 2.0 g / kg of glucose. Mizagliflozin, or water as the vehicle control, was then administered as a single oral dose to groups of male rats (n=8 / group) at doses of 0.03, 0.1, 0.3, and 1 mg / kg. Another control group was given vehicle and consisted of normal male Sprague Dawley rats that were not administrated STZ. Voglibose was also administered as a single oral dose to male rats (n=8 / group) at dose levels of 0.1, 0.3 and 1 mg / kg. Blood samples were collected just prior to loading with mixed carbohydrate and at 0.5, 1, 2, 3, 4, and 6 hours after loading. Plasma glucose concentrations were determined and ΔAUC0-1h for plasma glucose was calculated.
[0059] Mizagliflozin reduced plasma glucose concentrations (FIG.6) and significantly lowered the ΔAUC0-1 hrafter loading of glucose when compared to the vehicle control (FIG.7). A significant decrease in ΔAUC0-1 hrwas also seen after administration of voglibose. The ED50 calculated from the mean ΔAUC0-1h (% of control) for all dose levels of mizagliflozin was 0.099 mg / kg of mizagliflozin.
[0060] The dose-response relationships for mean ΔAUC0-1h (% of control) in response to mizagliflozin and voglibose are shown in FIG.8. The 50% effective dose (ED50) calculated from mean ΔAUC0-1h (% of control) was 0.099 mg / kg (as KGA-3235) in the case of mizagliflozin. Even ΔAUC0-1h in the group administrated maximum dose, 1 mg / kg of voglibose was not half or less than half that in the control group, and so ED50 of voglibose was not calculated. Example 4 - Study on plasma glucose levels in marmosets
[0061] Mizagliflozin was evaluated in the Diet-induced obese (DIO) marmoset, a polygenic non- human primate model of obesity. Rimonabant, a cannabinoid receptor (CB-1) antagonist that was marketed by Sanofi-Aventis for weight loss in obese patients, was administered at a maximal effective dose of 20 mg / kg twice daily as a positive control. Mizagliflozin was administered orally twice daily to DIO male marmosets (n=8 / group) for 2 weeks at BID doses of 3 and 30 mg / kg / day (or only vehicle, aqueous hydroxypropylmethyl- cellulose 0.1%). Effects on body weight and body composition, and serum chemistry parameters were measured and glucose excursions during post-treatment OGTTs were also determined after administration of an oral loading dose of glucose (2.0 g / kg). Doses of 3 and 30 mg / kg mizagliflozin had no significant effects on either body weight or body composition (fat or lean mass) or any serum chemistry parameters measured. Two weeks dosing with mizagliflozin resulted in a blunting of the glucose excursions during post- treatment OGTT’s (FIG.9). No signs of diarrhea were observed at any time during the study. Example 5 - Single dose study in humans
[0062] A single oral dose of 2 mg, 5 mg, 10 mg, 20 mg, 40 mg, 80 mg, and 160 mg of mizagliflozin were administered to healthy adult male volunteers by a placebo-controlled, randomized, double-blind method. The single dose was administered orally immediately before breakfast with approximately 200 mL of water after fasting for at least 10 hours. Pharmacodynamic effect parameters (blood glucose level, insulin, GLP 1, and gastric inhibitory polypeptide (GIP)) were measured, as indicated in Tables 3-6, respectively. Concentrations at each time point were measured, and summary statistics and coefficient variation (CV) were calculated for AUC0-t; t was up to 6 hours post dose. The time points were before administration and at 0.5, 1, 1.5, 2, 3, 4, 5, and 6 hours after administration. Blood glucose level and insulin were measured to evaluate, in an exploratory manner, the inhibitory effect on postprandial hyperglycemia. GLP-1 and GIP were measured to evaluate, in an exploratory manner, incretin secretory action. Table 3Table 4Table 5
[0063] Concerning the effect of mizagliflozin administration on the secretory action of incretin, suppression of GIP secretion was suggested (Table 6). AUC for GIP was lower in each mizagliflozin group, which indicated elevation of GIP secretion was suppressed. GIP concentrations peaked more than 3h after treatment. No clear conclusion could be reached regarding the effect on GLP-1 (Table 5). GLP-1 was higher in all mizagliflozin treatment groups but change in GLP-1 could not be evaluated due to variation in mean baseline level between subjects was large (1.9 to 9.9 pmol*h / L). Table 6Example 6 - Repeat dose study in humans
[0064] Oral doses of 2 mg, 5 mg, 10 mg, and 20 mg of mizagliflozin, placebo or miglitol 50 mg per dose three times daily to healthy adult male volunteers by a randomized, placebo-controlled, parallel-group, double-blind comparison method. The dose was orally administered with approximately 150 mL of water once daily immediately before breakfast on Days 1 and 13, and three times daily immediately before every meal on Days 3 to 12.
[0065] Changes in the following parameters and ΔAUC from 0 to t* hours after breakfast, lunch, and evening meal were measured: Blood glucose level, Serum insulin concentration, Blood active GLP-1 concentration, and Blood total GIP concentration, where t = 0.5, 1, 1.5, 2, and 3 (t = 0.5, 1, 1.5, 2, 3, and 5 only after breakfast), as indicated in Tabled 7, 8, 9, and 10, respectively.
[0066] In the miglitol group, hyperglycemia was suppressed after breakfast, lunch, and evening meal, as compared to the placebo group. In addition, inhibition of insulin secretion along with inhibition of hyperglycemia, an increase in total GLP-1 concentration, a tendency toward increases in active GLP-1 concentration, and inhibition of increase in total GIP concentration were seen. In the mizagliflozin group, hyperglycemia was suppressed after breakfast, lunch, and evening meal on a level equivalent to the miglitol group. In the mizagliflozin group, inhibition of insulin secretion along with inhibition of hyperglycemia was seen the same as in the miglitol group. In the mizagliflozin group, an increase in total GLP-1 concentration was seen on a level equivalent to the miglitol group. In the mizagliflozin group, a tendency toward increase in active GLP-1 concentration was seen as in the case of the miglitol group. In the mizagliflozin group, decrease in total GIP concentration was seen on a level equivalent to the miglitol group. These pharmacodynamic effects more or less persisted during 10-day repeated administration. There was no correlation between plasma mizagliflozin concentration and the pharmacodynamic effects. Measurements in Tables 7-10 were performed on Day 3 after breakfast. Table 7Table 8Table 9Table 10
[0067] Glucose nadir (0-3 h) post-meal challenge was higher in all doses examined.Table 11 - Glucose Nadir, change from Baseline
[0068] Glucose nadir (0-3 h) post-meal challenge was higher in all doses examined. Change in glucose nadir was calculated for subjects with hypoglycemia (<70 mg / dL) and subjects that did not become hypoglycemic (>70 mg / dL) at baseline. For the All Capsules, performing a t-test using mixed model analysis resulted in a p-value = 0.045 Table 12 - Glucose Nadir-Change from Baseline, Hypoglycemic vs Non-Hypoglycemic
[0069] Peak Glucose was calculated for all subjects at baseline and with mizagliflozin dosing. The change in peak glucose is presented here. Peak glucose (0-3 h) post-meal challenge was reduced in all doses examined. For the All Capsules, performing a t-test using mixed model analysis resulted in a p-value = 0.027 Table 13 - Peak Glucose, change from Baseline
[0070] Peak insulin (0-3 h post-meal challenge) was reduced in all doses examined. For the All Capsules, performing a t-test using mixed model analysis resulted in a p-value = 0.012 Table 14 - Peak Insulin, change from Baseline
Claims
Claims:
1. A method of treating a disorder in a subject in need thereof, the method comprising administering one or more SGLT1 inhibitors or a pharmaceutically acceptable salt thereof, wherein the disorder is known to be responsive to the administration of ketogenic composition or low carbohydrate diet.
2. The method of claim 1, wherein the disorder is a neurological disorder.
3. The method of claim 2, wherein the neurological disorder is neurological seizures.
4. The method of claim 2, wherein the disorder is epilepsy, Dravet’s Syndrome, stroke, brain trauma, depression, mitochondrial defects in complexes I, II, and IV.
5. The method of claim 2, wherein the disorder is Parkinson’s disease, amyotrophic lateral sclerosis, Alzheimer autism, or migraine.
6. The method of claim 1, wherein the disorder is cancer or type 2 diabetes mellitus that is primarily driven by elevated postprandial glucose levels.
7. A method of treating a disorder according to any of claims 1-6, comprising orally administering an effective amount of an SGLT1 inhibitor compound of Formula I or II, or an effective amount of a pharmaceutically acceptable salt of an SGLT1 inhibitor compound of Formula I or II, to the subject, wherein the compound of Formula I is:Formula I; wherein R1represents H, or an optionally substituted C1-6alkyl group;one of Q and T represents a group:, while the other represents a C1-6alkyl group, a halo(C1-6alkyl) group, a C1-6alkoxy-substituted (C1-6alkyl) group or a C3-7cycloalkyl group; R2represents a hydrogen atom, a halogen atom, a hydroxy group, a C1-6alkyl group, a C1-6alkoxy group, a C1-6alkylthio group, a halo(C1-6alkyl) group, a halo(C1-6alkoxy) group, a C1-6alkoxy-substituted (C1-6alkoxy) group, a C3-7cycloalkyl-substituted ( C2-6alkoxy) group or —A—RAin which A represents a single bond, an oxygen atom, a methylene group, an ethylene group, —OCH2— or —CH2O—; and RArepresents a C3-7cycloalkyl group, a C2-6heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkyl group, a C1-6alkoxy group, a C2-6alkenyloxy group, a halo(C1-6alkyl) group, a hydroxy(C1-6alkyl) group, a carboxy group, a C2-7alkoxycarbonyl group, a cyano group and a nitro group, or a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom and a C1-6alkyl group; X represents a single bond, an oxygen atom or a sulfur atom; Y represents a C1-6alkylene group which may be substituted by a hydroxy group or a C2-6alkenylene group; Z represents —RB, —CORC, —SO2RC, —CON(RD)RE, —SO2NHRFor —C(═NRG)N(RH)RI; RCrepresents an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkylsulfonylamino group, a C1-6alkyl group and a C1-6alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of ahalogen atom, an amino group and a C1-6alkyl group, or a C1-6alkyl group which may have the same or different 1 to 5 groups selected from the following substituent group (i); R4, RB, RD, REand RFare the same or different, and each represents a hydrogen atom, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkylsulfonylamino group, a C1-6alkyl group and a C1-6alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom, an amino group and a C1-6alkyl group, or a C1-6alkyl group which may have the same or different 1 to 5 groups selected from the following substituent group (i), or both of R4 and RBbind together with the neighboring nitrogen atom to form a C2-6cyclic amino group which may have a substituent selected from the group consisting of a hydroxy group, a carbamoyl group, a C1-6alkyl group, an oxo group, a carbamoyl(C1-6alkyl) group, a hydroxy(C1-6alkyl) group and a C1-6alkylsulfonylamino-substituted (C1-6alkyl) group, or both of RDand REbind together with the neighboring nitrogen atom to form a C2-6cyclic amino group which may have a substituent selected from the group consisting of a hydroxy group, a carbamoyl group, a C1-6alkyl group, an oxo group, a carbamoyl(C1-6alkyl) group, a hydroxy(C1-6alkyl) group and a C1-6alkylsulfonylamino-substituted (C1-6alkyl) group; RG, RHand RIare the same or different, and each represents a hydrogen atom, a cyano group, a carbamoyl group, a C2-7acyl group, a C2-7alkoxycarbonyl group, an aryl(C2-7alkoxycarbonyl) group, a nitro group, a C1-6alkylsulfonyl group, a sulfamide group, a carbamimidoyl group, or a C1-6alkyl group which may have the same or different 1 to 5 groups selected from the following substituent group (i), or both of RGand RHbind to form an ethylene group, or both of RHand RIbind together with the neighboring nitrogen atom to form a C2-6cyclic amino group which may have a substituent selected from the group consisting of a hydroxy group, a carbamoyl group, a C1-6alkyl group, an oxo group, a carbamoyl(C1-6alkyl) group, a hydroxy(C1-6alkyl) group and a C1-6alkylsulfonylamino-substituted (C1-6alkyl) group; R3, R5and R6are the same or different, and each represents a hydrogen atom, a halogen atom, a C1-6alkyl group or a C1-6alkoxy group; and substituent group (i) consists of a hydroxy group, a C1-6alkoxy group, a C1-6alkylthio group, an amino group, a mono or di(C1-6alkyl)amino group, a mono or di[hydroxy(C1-6alkyl)]amino group, an ureido group, a sulfamide group, a mono or di(C1-6alkyl)ureido group, a mono or di(C1-6alkyl)sulfamide group, a C2-7acylamino group, a C1-6alkylsulfonylamino group, a C1-6alkylsulfonyl group, a carboxy group, a C2-7alkoxycarbonyl group, —CON(RJ)RKin which RJand RKare the same or different, and each represents a hydrogen atom or a C1-6alkyl group which may have the same or different 1 to 3 substituents selected from the group consisting of a hydroxy group, an amino group, a mono or di(C1-6alkyl)amino group, a mono or di[hydroxy(C1-6alkyl)]amino group, an ureido group, a mono or di(C1-6alkyl)ureido group, a C2-7acylamino group, a C1-6alkylsulfonylamino group and a carbamoyl group, or both of RJ and RK bind together with the neighboring nitrogen atom to form a C2-6cyclic amino group which may have a substituent selected from thegroup consisting of a hydroxy group, a carbamoyl group, a C1-6alkyl group, an oxo group, a carbamoyl(C1-6alkyl) group, a hydroxy(C1-6alkyl) group and a C1-6alkylsulfonylamino-substituted (C1-6alkyl) group, an aryl(C1-6alkoxy) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkyl group and a C1-6alkoxy group on the ring, an aryl(C1-6alkylthio) group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkyl group and a C1-6alkoxy group on the ring, a C3-7cycloalkyl group, a C2-6heterocycloalkyl group, an aryl group which may have the same or different 1 to 3 substituents selected from the group consisting of a halogen atom, a hydroxy group, an amino group, a C1-6alkylsulfonylamino group, a C1-6alkyl group and a C1-6alkoxy group, a heteroaryl group which may have a substituent selected from the group consisting of a halogen atom, an amino group and a C1-6alkyl group, a C2-6cyclic amino group which may have a substituent selected from the group consisting of a hydroxy group, a carbamoyl group, a C1-6alkyl group, an oxo group, a carbamoyl(C1-6alkyl) group, a hydroxy(C1-6alkyl) group and a C1-6alkylsulfonylamino-substituted (C1-6alkyl) group, and a C1-4aromatic cyclic amino group which may have a C1-6alkyl group as a substituent; and wherein the compound of Formula II is:wherein R7is hydrogen or optionally substituted C1-10-alkyl, C1-5-cycloalkyl, or 5-membered heterocycle, which optional substitution is with one or more R7A; each R7Ais independently amino, ester, amide, thiol, carboxylic acid, cyano, halo, hydroxyl, or optionally substituted C1-4-alkoxy, C1-5-cycloalkyl, or 5-membered heterocycle, which optional substitution is with one or more R7B; each R7B is independently C1-4-alkyl, halo, or hydroxyl; n is 0, 1, or 2; each R8is independently F or OR8A, wherein eachR8Ais independently hydrogen, C1-4-alkyl, or acyl; each R9is independently halo, hydroxyl, or optionally substituted C1-10-alkyl or C1-10-alkoxy, which optional substitution is with one or more R9A; each R9Ais independently amino, ester, amide, thiol, carboxylic acid, cyano, halo, hydroxyl, or optionally substituted C1-4-alkoxy, C1-5-cycloalkyl, or 5-membered heterocycle,which optional substitution is with one or more R9B; each R9Bis independently C1-4-alkyl, amino, cyano, halo, or hydroxyl; p is 0, 1, or 2; each R10is independently R10A, —N(R10A)(R10B), —OR10A, —SR10A, —S(O)R10A, or —S(O)2R10A; R10Ais optionally substituted C4-20-alkyl or 4-20-membered heteroalkyl, which optional substitution is with one or more R10C, and which is optionally attached to another R10Amoiety to provide a dimer or trimer; R10Bis hydrogen or R10A; each R10Cis independently amino, amido, azo, carbonyl, carboxyl, cyano, formyl, guanidino, halo, hydroxyl, imido, imino, isothiocyanate, nitrile, nitro, nitroso, nitroxy, oxo, sulfanyl, sulfinyl, sulfonyl, thial, thiocyanate, thione, thiourea, urea, or X1, X1-L1-X2, or X1-L1-X2-L2-X3, wherein each of X1, X2and X3is independently optionally substituted C1-4-alkyl, C1-6-cycloalkyl, 5- or 6-membered heterocycle, or aryl, which optional substitution is with one or more R10D, and each of L1 and L2 is independently optionally substituted C1-6-alkyl or 1-10-membered heteroalkyl, which optional substitution is with one or more of R10E; each R10Dis independently R10Eor C1-6-alkyl optionally substituted with one or more of R10E; each R10Eis independently amino, amido, azo, carbonyl, carboxyl, cyano, formyl, guanidino, halo, hydroxyl, imido, imino, isothiocyanate, nitrile, nitro, nitroso, nitroxy, oxo, sulfanyl, sulfinyl, sulfonyl, thial, thiocyanate, thione, or urea; and m is 1, 2 or 3; wherein the SGLT1 inhibitor compound has a primary site of pharmacological action in the intestinal lumen of the subject.
8. The method of treating a disorder according to claim 7, wherein the SGLT1 inhibitor compound is selected from the group consisting of:,.
9. The method of treating a disorder according to any one of claims 1-6, wherein the pharmaceutical salt of the SGLT1 inhibitor compound is selected from monosebacate and hemifumarate dehydrate of the compound.
10. The method of treating a disorder according to any one of claims 1-8, wherein the SGLT1 inhibitor compound, or pharmaceutically acceptable salt thereof, is administered at a dosage of from about 0.1 mg / day to about 60 mg / day.
11. The method of treating a disorder according to any one of claims 1-10 wherein the SGLT1 inhibitor compound, or pharmaceutically acceptable salt thereof, is administered as a unit dose of, from about 0.1 mg to about 20 mg, one to three times a day.
12. The method of treating a disorder according to any one of claims 1-6, wherein the pharmaceutical salt is selected from mizagliflozin monosebacate and mizagliflozin hemifumarate dehydrate.
13. The method of treating a disorder according to claim 12, wherein the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered at a dosage of from about 1 mg / day to about 100 mg / day.
14. The method of treating a disorder according to claim 12, wherein the mizagliflozin, or pharmaceutically acceptable salt thereof, is administered at a dosage of, from about 1 mg to about 100 mg, two or three times a day.
Citation Information
Patent Citations
Pyrazole derivatives, medicinal composition containing the same, medicinal use thereof, and intermediate for production thereof
US20050272669A1
Method for treating post-prandial hypoglycemia
US20210085701A1
Compositions and methods for treating metabolic disease
US20220257624A1
